Ovid Therapeutics Inc (OVID) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access OVID Annual Balance Sheets →
Looking at balance sheet data from Ovid Therapeutics Inc through Jun 30 2025 provides insight into Jun 30 2026's solvency and capital structure over time.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent169.77
Available-for-sale Securities, Debt Securities, Current MA0.00
Cash & Short-term Investments169.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current6.40
Total Current Assets123.62
Equipment/Property/Plant Net0.20
Long-term investments52.55
Other Assets, Noncurrent3.05
Restricted Cash11.30
Total Assets231.97
Liabilities
Accounts Payable, Current AC4.07
Accrued Liabilities, Current AC4.42
Other Liabilities, Current1.30
Taxes Payable0.18
Total Current Liabilities9.98
Total Long-term Debt0.00
Other liabilities, Noncurrent12.10
Operating Lease Liability Current1.46
Total Liabilities22.08
Stockholders' Equity
Common Stock Value0.19
Additional Paid In Capital Common Stock564.17
Retained Earnings / Accumulated Deficit-353.71
Accumulated Other Comprehensive Income-0.75
Other Equity-0.75
Common Stockholder's Equity209.89
Total Stockholder's Equity209.89
Liabilities & Stockholder's Equity231.97
4 historic quarters locked

Sign in to unlock the full Ovid Therapeutics Inc balance sheet history.

About Ovid Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001628280-26-056498

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.